pdufa.bio
Home › Decisions › AZN 2026-05-22

AZN FDA decision — May 22, 2026

✓ APPROVED

AstraZeneca PLC — Datopotamab Deruxtecan (Dato-DXd) - (TROPION · Metastatic triple negative breast cancer (TNBC).

Run-up into the decision (T-120 → T+5)

PDUFA 5/22/26$209.48$179.6412/5/25
Daily close, T-120 (12/5/25) through T+5. Run-up high $209.48 on 2/18/26, low $179.64 on 12/16/25 (T-120 to T-1). FDA decision 5/22/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-05-22
OutcomeApproved
Drug / candidateDatopotamab Deruxtecan (Dato-DXd) - (TROPION
CompanyAstraZeneca PLC
120-day run-up (T-120→T-1)+2.3%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio